Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 6;20(6):e0325417.
doi: 10.1371/journal.pone.0325417. eCollection 2025.

The TMA team and TTP pathway improved outcomes in a cohort with Thrombotic thrombocytopenic purpura

Samuel A Merrill  1   2 , Stephen Yu  2 , Sylvia E Webber  2 , John Gotses  3 , Emma L Platt  4 , Ruta Arays  5 , Aaron D Shmookler  6
Affiliations

The TMA team and TTP pathway improved outcomes in a cohort with Thrombotic thrombocytopenic purpura

Samuel A Merrill et al. PLoS One. .

Abstract

Background: Providing optimal care for patients with thrombotic thrombocytopenic purpura (TTP) is challenging because of multiple involved specialties, knowledge gaps, and a high rate of disease relapse. A thrombotic microangiopathy (TMA) Team and TTP Pathway could improve outcomes.

Objectives: To assess if a structured TTP Pathway, supported by a TMA Team, improved TTP care by reducing TTP relapse and TTP-related death (TTP-RRD) at a rural Appalachian medical center.

Methods: Prospective cohort quality improvement project using the DMAIC quality improvement framework (Define, Measure, Analyze, Improve, Control) to develop a TMA Team and TTP Pathway. Pathway care included standardized use of therapeutic plasma exchange (TPE), rituximab, caplacizumab, as well as improved coordination between medical services, and regular outpatient biochemical TTP surveillance. Outcomes were determined by retrospective chart review for patients with acute TTP treated with usual care (N = 16 episodes) and the TTP Pathway (N = 16 episodes).

Results and conclusions: All patients had acquired TTP. TTP-RRD at 90 days was reduced from 69% with usual care to 6% with Pathway care (95% CI 0.35 to 0.90, P = 0.0004), a relative risk reduction of 91%; TTP relapse alone at 90 days was reduced from 62% to 0% (95% CI 0.36 to 0.88, P = 0.0002) with Pathway care. The number needed to treat to prevent TTP-RRD was 1.59 at 90 days. Over the project duration usual care demonstrated a hazard ratio for TTP-RRD of 12.58 compared to Pathway care. With the intervention, the duration of TPE was increased (median 6 vs 12 sessions, P < 0.05), as was use of rituximab (31.3% vs 93.8%, 95% CI -0.36 to -0.88, P = 0.003), and caplacizumab (6.3% vs 62.5%, 95% CI -0.027 to -0.81, P = 0.001). All Pathway patients underwent biochemical surveillance, and 31% had pre-emptive rituximab to reduce possibility of clinical relapse. A structured TTP Pathway significantly reduces morbidity and aligns care with modern clinical guidelines. The TMA Team is a valuable institutional resource to improve outcomes.

PubMed Disclaimer

Conflict of interest statement

SAM reports previous consultancy for Genentech, Sanofi, and the American Society of Hematology. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Primary outcome of TTP-RRD.
Kaplan-Meier analysis of all patients with acute TTP treated with usual care or TTP Pathway care during the study period, with long-rank testing indicated.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585–94. doi: 10.1056/NEJM199811263392203 - DOI - PMC - PubMed
    1. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, et al.. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496–502. doi: 10.1111/jth.15010 - DOI - PMC - PubMed
    1. Cataland SR, Kourlas PJ, Yang S, Geyer S, Witkoff L, Wu H, et al.. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. Blood Adv. 2017;1(23):2075–82. doi: 10.1182/bloodadvances.2017009308 - DOI - PMC - PubMed
    1. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al.. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393–7. doi: 10.1056/NEJM199108083250604 - DOI - PubMed
    1. Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, et al.. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023;38(2):77–278. doi: 10.1002/jca.22043 - DOI - PubMed

LinkOut - more resources